Guang Yang

Guang Yang

Auto-generated profile, based on publicly available information

Guang Yang

Department of Pharmacology, Center for Pharmacogenomics, Feinberg School of Medicine, Northwestern University, Chicago, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Bone
Verified
Journal Article
Open access
GYGuang Yang
Guang Yang
SSSonal Singh
Sonal Singh
YCYiqing Chen
Yiqing Chen
IHIssam S. Hamadeh
Issam S. Hamadeh
TLTaimour Langaee
Taimour Langaee
YGYan Gong
Yan Gong
Osteonecrosis of the jaw (ONJ) is a rare but serious drug induced adverse event, mainly associated with the use of antiresorptive medications, such as intravenous (IV) bisphosphonates (BPs) in cancer patients. In this review, we evaluated all the pharmacogenomic association studies for ONJ published up to December 2018. To date, two SNPs (CYP2C8 rs1934951 and RBMS3 rs17024608) were identified to be associated with ONJ by two genome-wide association studies (GWAS). However, all six subsequent candidate gene studies failed to replicate these results. In addition, six discovery candidate gene studies tried to identify the genetic markers in several genes associated with bone remodeling, bone mineral density, or osteoporosis. After evaluating the results of these 6 studies, none of the SNPs was significantly associated with ONJ. Recently, two whole-exome sequencing (WES) analysis (including one from our group) were performed to identify variants associated with ONJ. So far, only our study successfully replicated discovery result indicating SIRT1 SNP rs7896005 to be associated with ONJ. However, this SNP also did not reach genome-wide significance. The major limitations of these studies include lack of replication phases and limited sample sizes. Even though some studies had larger sample sizes, they recruited healthy individuals as controls, not subjects treated with BPs. We conclude that a GWAS with a larger sample size followed by replication phase will be needed to fully investigate the pharmacogenomic markers of ONJ.

16 January 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GYGuang Yang
Guang Yang
MMMrinal Mishra
Mrinal Mishra
MPMinoli A. Perera
Minoli A. Perera

23 October 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
GYGuang Yang
Guang Yang
JCJoseph M. Collins
Joseph M. Collins
RRRoya Rafiee
Roya Rafiee
SSSonal Singh
Sonal Singh
TLTaimour Langaee
Taimour Langaee
YGYan Gong
Yan Gong
Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug reaction. Our previous whole‐exome sequencing study found SIRT1 intronic region SNP rs7896005 to be associated with MRONJ in cancer patients treated with intravenous (IV) bisphosphonates (BPs). This study aimed to identify causal variants for this association. In silico analyses identified three SNPs (rs3758391, rs932658, and rs2394443) in the SIRT1 promoter region that are in high linkage disequilibrium (r2 > 0.8) with rs7896005. To validate the association between these SNPs and MRONJ, we genotyped these three SNPs on the germline DNA from 104 cancer patients of European ancestry treated with IV BPs (46 cases and 58 controls). Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ. The odds ratios (95% confidence interval) and p values were 0.351 (0.164‐0.751) (p=0.007) for rs3758391, 0.351 (0.164‐0.751) (p=0.007) for rs932658, and 0.331 (0.157‐0.697) (p=0.0036) for rs2394443, respectively. In the reporter gene assays, constructs containing rs932658 with variant allele A had higher luciferase activity than the reference allele, while constructs containing SNP rs3758391 and/or rs2394443 did not significantly affect activity. These results indicate that the promoter SNP rs932658 regulates the expression of SIRT1 and presumably lowers the risk of MRONJ by increasing SIRT1 expression.

20 March 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
SSSonal Singh
Sonal Singh
CMCaitrin W. McDonough
Caitrin W. McDonough
YGYan Gong
Yan Gong
WAWael Alghamdi
Wael Alghamdi
MAMeghan J. Arwood
Meghan J. Arwood
JJJulie A. Johnson
Julie A. Johnson
Background: Thiazide and thiazide‐like diuretics are first‐line medications for treating uncomplicated hypertension. However, their use has been associated with adverse metabolic events, including hyperglycemia and incident diabetes mellitus, with incompletely understood mechanisms. Our goal was to identify genomic variants associated with thiazide‐like diuretic/chlorthalidone‐induced glucose change. Methods and Results: Genome‐wide analysis of glucose change after treatment with chlorthalidone was performed by race among the white (n=175) and black (n=135) participants from the PEAR ‐2 (Pharmacogenomic Evaluation of Antihypertensive Responses‐2). Single‐nucleotide polymorphisms with P <5×10 −8 were further prioritized using in silico analysis based on their expression quantitative trait loci function. Among blacks, an intronic single‐nucleotide polymorphism (rs9943291) in the HMGCS 2 was associated with increase in glucose levels following chlorthalidone treatment (ß=12.5; P =4.17×10 −8 ). G‐allele carriers of HMGCS 2 had higher glucose levels (glucose change=+16.29 mg/dL) post chlorthalidone treatment compared with noncarriers of G allele (glucose change=+2.80 mg/dL). This association was successfully replicated in an independent replication cohort of hydrochlorothiazide‐treated participants from the PEAR study (ß=5.54; P =0.023). A meta‐analysis of the 2 studies was performed by race in Meta‐Analysis Helper, where this single‐nucleotide polymorphism, rs9943291, was genome‐wide significant with a meta‐analysis P value of 3.71×10 −8 . HMGCS 2 , a part of the HMG ‐CoA synthase family, is important for ketogenesis and cholesterol synthesis pathways that are essential in glucose homeostasis. Conclusions: These results suggest that HMGCS 2 is a promising candidate gene involved in chlorthalidone and Hydrochlorothiazide (HCTZ)‐induced glucose change. This may provide insights into the mechanisms involved in thiazide‐induced hyperglycemia that may ultimately facilitate personalized approaches to antihypertensive selection for hypertension treatment. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifiers: NCT 00246519 and NCT 01203852.

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
GYGuang Yang
Guang Yang
RWRoy Williams
Roy Williams
LWLishu Wang
Lishu Wang
NFNosha Farhadfar
Nosha Farhadfar
YCYiqing Chen
Yiqing Chen
YGYan Gong
Yan Gong

27 January 2025 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GYGuang Yang
Guang Yang
CACristina Alarcon
Cristina Alarcon
CCCatherine Chanfreau
Catherine Chanfreau
NLNorman H. Lee
Norman H. Lee
PFPaula Friedman
Paula Friedman
MPMinoli A. Perera
Minoli A. Perera
Clopidogrel, an anti‐platelet drug, is used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic events, with African Americans (AA) suffering disproportionately. The aim of this study was to discover novel biomarkers of clopidogrel resistance in African Americans using genome and transcriptome data. We conducted a genome‐wide association study (GWAS), including local ancestry adjustment, in 141 AA on clopidogrel to identify genetic associations with high on‐treatment platelet reactivity (HTPR), with validation of genome‐wide significant and suggestive loci in an independent cohort of AA clopidogrel patients (N = 823) from the Million Veteran's Program (MVP) along with in vitro functional analysis. We performed differential gene expression (DGE) analysis in whole blood to identify transcriptomic predictors of response, followed by functional validation in MEG‐01 cells. GWAS identified one signal on Chromosome 7 as significantly associated with increasing risk of HTPR. The lead single‐nucleotide polymorphism (SNP), rs7807369, within thrombospondin 7A (THSD7A) was associated with an increased risk of HTPR (odds ratio (OR) = 4.02, P = 4.56 × 10−9). Higher THSD7A gene expression was associated with HTPR in an independent cohort of clopidogrel‐treated patients (P = 0.004) and carrying a risk allele showed increased gene expression in primary human endothelial cells. Notably, the CYP2C19*2 variants showed no association with clopidogrel response in the discovery or MVP cohorts. DGE analysis identified an association with decreased LAIR1 and AP3B2 expression to HTPR. LAIR1 knockdown in MEG‐01 cells resulted in increased expression of SYK and AKT1, suggesting an inhibitory role of LAIR1 in the Glycoprotein VI pathway. In summary, these findings suggest that other variants and genes outside of CYP2C19 star alleles play an important role in clopidogrel response in AA.